吉田 博徳

最終更新日時: 2020/07/27 17:40:21

印刷する

氏名(漢字/フリガナ/アルファベット表記)
吉田 博徳/ヨシダ ヒロノリ/Yoshida, Hironori
所属部署・職名(部局/所属/講座等/職名)
医学部附属病院/呼吸器内科/特定病院助教
所属学会(国内)
学会名(日本語) 学会名(英語)
日本臨床腫瘍学会 Japanese Society of Medical Oncology
日本癌学会 Japanese Cancer Association
日本肺癌学会 The Japan Lung Cancer Society
日本呼吸器学会 The Japanese Respiratory Society
日本内科学会 The Japanese Society of Internal Medicine
日本呼吸器内視鏡学会 The Japan Society for Respiratory Endoscopy
所属学会(海外)
学会名(英語) 国名
ASCO 米国
IASLC
使用言語
言語名(japanese) 言語名(english) コード
日本語 Japanese jpn
ORCID ID
https://orcid.org/0000-0002-1676-0173
researchmap URL
https://researchmap.jp/h1ghh1gh-B
研究テーマ
(日本語)
肺癌の臨床研究 ・肺癌のトランスレーショナルリサーチ
論文
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Ryo Nakanobo, Masatsugu Hamaji, Akihiro Ohsumi, Sho Koyasu, Hironori Yoshida, Hiroaki Ozasa, Masahide Isowa, Naoki Nakajima, Akihiko Yoshizawa, Hiroshi Date Ryo Nakanobo, Masatsugu Hamaji, Akihiro Ohsumi, Sho Koyasu, Hironori Yoshida, Hiroaki Ozasa, Masahide Isowa, Naoki Nakajima, Akihiko Yoshizawa, Hiroshi Date Ryo Nakanobo, Masatsugu Hamaji, Akihiro Ohsumi, Sho Koyasu, Hironori Yoshida, Hiroaki Ozasa, Masahide Isowa, Naoki Nakajima, Akihiko Yoshizawa, Hiroshi Date Paratracheal Middle Mediastinal Thymic Carcinomas. Paratracheal Middle Mediastinal Thymic Carcinomas. Paratracheal Middle Mediastinal Thymic Carcinomas. The Annals of thoracic surgery, 110, 1, e39-e41 The Annals of thoracic surgery, 110, 1, e39-e41 The Annals of thoracic surgery, 110, 1, e39-e41 2020/07 英語 公開
Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. Molecular cancer therapeutics, 19, 6, 1320-1327 Molecular cancer therapeutics, 19, 6, 1320-1327 Molecular cancer therapeutics, 19, 6, 1320-1327 2020/06 英語 研究論文(学術雑誌) 公開
Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada, Kenichi Yoshimura, Masataka Hirabayashi, Toyohiro Hirai Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada, Kenichi Yoshimura, Masataka Hirabayashi, Toyohiro Hirai Hironori Yoshida, Young Hak Kim, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Toshihiko Kaneda, Hiroshige Yoshioka, Hiroaki Nakagawa, Keisuke Tomii, Asuka Okada, Kenichi Yoshimura, Masataka Hirabayashi, Toyohiro Hirai A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer research, 40, 5, 2981-2987 Anticancer research, 40, 5, 2981-2987 Anticancer research, 40, 5, 2981-2987 2020/05 英語 研究論文(学術雑誌) 公開
Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression. Cell death & disease, 11, 3, 177-177 Cell death & disease, 11, 3, 177-177 Cell death & disease, 11, 3, 177-177 2020/03/09 英語 研究論文(学術雑誌) 公開
HIRONORI YOSHIDA, HIROKI NAGAI, YUICHI SAKAMORI, HIROAKI OZASA, TAKASHI NISHIMURA, KEISUKE TOMII, TOYOHIRO HIRAI, YUKINORI MATSUO, YUSUKE IIZUKA, TAKASHI MIZOWAKI, KENICHI YOSHIMURA, YOUNG HAK KIM HIRONORI YOSHIDA, HIROKI NAGAI, YUICHI SAKAMORI, HIROAKI OZASA, TAKASHI NISHIMURA, KEISUKE TOMII, TOYOHIRO HIRAI, YUKINORI MATSUO, YUSUKE IIZUKA, TAKASHI MIZOWAKI, KENICHI YOSHIMURA, YOUNG HAK KIM HIRONORI YOSHIDA, HIROKI NAGAI, YUICHI SAKAMORI, HIROAKI OZASA, TAKASHI NISHIMURA, KEISUKE TOMII, TOYOHIRO HIRAI, YUKINORI MATSUO, YUSUKE IIZUKA, TAKASHI MIZOWAKI, KENICHI YOSHIMURA, YOUNG HAK KIM Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer In Vivo, 34, 2, 897-902 In Vivo, 34, 2, 897-902 In Vivo, 34, 2, 897-902 2020/03 研究論文(学術雑誌) 公開
Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo Ryusuke Hatae, Kenji Chamoto, Young Hak Kim, Kazuhiro Sonomura, Kei Taneishi, Shuji Kawaguchi, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Maryam Akrami, Sidonia Fagarasan, Izuru Masuda, Yasushi Okuno, Fumihiko Matsuda, Toyohiro Hirai, Tasuku Honjo Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI insight, 5, 2 JCI insight, 5, 2 JCI insight, 5, 2 2020/01/30 英語 研究論文(学術雑誌) 公開
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nature communications, 11, 1, 74-74 Nature communications, 11, 1, 74-74 Nature communications, 11, 1, 74-74 2020/01/03 英語 研究論文(学術雑誌) 公開
Hironori Yoshida, Young Hak Kim, Shigeaki Iwatsubo, Chikara Sakaguchi, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Tadashi Mio, Toyohiro Hirai Hironori Yoshida, Young Hak Kim, Shigeaki Iwatsubo, Chikara Sakaguchi, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Tadashi Mio, Toyohiro Hirai Hironori Yoshida, Young Hak Kim, Shigeaki Iwatsubo, Chikara Sakaguchi, Yuichi Sakamori, Hiroki Nagai, Hiroaki Ozasa, Tadashi Mio, Toyohiro Hirai Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. Oncology, 98, 7, 460-467 Oncology, 98, 7, 460-467 Oncology, 98, 7, 460-467 2020 英語 研究論文(学術雑誌) 公開
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Scientific reports, 9, 1, 17085-17085 Scientific reports, 9, 1, 17085-17085 Scientific reports, 9, 1, 17085-17085 2019/11/19 英語 研究論文(学術雑誌) 公開
Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Ryoko Okutani, Yuto Yasuda, Takashi Nomizo, Kiyoshi Uemasu, Koichi Hasegawa, Hironori Yoshida, Yoshitaka Yagi, Hiroki Nagai, Yuichi Sakamori, Mitsuyoshi Ueda, Toyohiro Hirai, Young Hak Kim Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Ryoko Okutani, Yuto Yasuda, Takashi Nomizo, Kiyoshi Uemasu, Koichi Hasegawa, Hironori Yoshida, Yoshitaka Yagi, Hiroki Nagai, Yuichi Sakamori, Mitsuyoshi Ueda, Toyohiro Hirai, Young Hak Kim Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, Hitomi Ajimizu, Ryoko Okutani, Yuto Yasuda, Takashi Nomizo, Kiyoshi Uemasu, Koichi Hasegawa, Hironori Yoshida, Yoshitaka Yagi, Hiroki Nagai, Yuichi Sakamori, Mitsuyoshi Ueda, Toyohiro Hirai, Young Hak Kim Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Molecular cancer research : MCR, 17, 1, 212-224 Molecular cancer research : MCR, 17, 1, 212-224 Molecular cancer research : MCR, 17, 1, 212-224 2019/01 英語 研究論文(学術雑誌) 公開
Kohei Fujita, Young Hak Kim, Osamu Kanai, Hironori Yoshida, Tadashi Mio, Toyohiro Hirai Kohei Fujita, Young Hak Kim, Osamu Kanai, Hironori Yoshida, Tadashi Mio, Toyohiro Hirai Kohei Fujita, Young Hak Kim, Osamu Kanai, Hironori Yoshida, Tadashi Mio, Toyohiro Hirai Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respiratory medicine, 146, 66-70 Respiratory medicine, 146, 66-70 Respiratory medicine, 146, 66-70 2019/01 英語 研究論文(学術雑誌) 公開
HIRONORI YOSHIDA, YOUNG HAK KIM, HIROAKI OZASA, YUICHI SAKAMORI, TAKAHIRO TSUJI, TAKASHI NOMIZO, YUTO YASUDA, TOMOKO YAMAMOTO, HITOMI AJIMIZU, TOYOHIRO HIRAI HIRONORI YOSHIDA, YOUNG HAK KIM, HIROAKI OZASA, YUICHI SAKAMORI, TAKAHIRO TSUJI, TAKASHI NOMIZO, YUTO YASUDA, TOMOKO YAMAMOTO, HITOMI AJIMIZU, TOYOHIRO HIRAI HIRONORI YOSHIDA, YOUNG HAK KIM, HIROAKI OZASA, YUICHI SAKAMORI, TAKAHIRO TSUJI, TAKASHI NOMIZO, YUTO YASUDA, TOMOKO YAMAMOTO, HITOMI AJIMIZU, TOYOHIRO HIRAI Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer In Vivo, 32, 6, 1587-1590 In Vivo, 32, 6, 1587-1590 In Vivo, 32, 6, 1587-1590 2018/11 研究論文(学術雑誌) 公開
Hironori Yoshida, Masahiro Ooi, Young Hak Kim Hironori Yoshida, Masahiro Ooi, Young Hak Kim Hironori Yoshida, Masahiro Ooi, Young Hak Kim Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13, 11, e219-e220 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13, 11, e219-e220 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13, 11, e219-e220 2018/11 英語 公開
Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai Osamu Kanai, Young Hak Kim, Yoshiki Demura, Makiko Kanai, Tsuyoshi Ito, Kohei Fujita, Hironori Yoshida, Masaya Akai, Tadashi Mio, Toyohiro Hirai Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thoracic cancer, 9, 7, 847-855 Thoracic cancer, 9, 7, 847-855 Thoracic cancer, 9, 7, 847-855 2018/07 英語 研究論文(学術雑誌) 公開
H. Yoshida, Y.H. Kim, H. Ozasa, H. Nagai, Y. Sakamori, T. Tsuji, T. Nomizo, Y. Yasuda, T. Funazo, T. Hirai H. Yoshida, Y.H. Kim, H. Ozasa, H. Nagai, Y. Sakamori, T. Tsuji, T. Nomizo, Y. Yasuda, T. Funazo, T. Hirai H. Yoshida, Y.H. Kim, H. Ozasa, H. Nagai, Y. Sakamori, T. Tsuji, T. Nomizo, Y. Yasuda, T. Funazo, T. Hirai Nivolumab in non-small-cell lung cancer with EGFR mutation Nivolumab in non-small-cell lung cancer with EGFR mutation Nivolumab in non-small-cell lung cancer with EGFR mutation Annals of Oncology, 29, 3, 777-778 Annals of Oncology, 29, 3, 777-778 Annals of Oncology, 29, 3, 777-778 2018/03 研究論文(学術雑誌) 公開
Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Molecular and clinical oncology, 7, 4, 677-680 Molecular and clinical oncology, 7, 4, 677-680 Molecular and clinical oncology, 7, 4, 677-680 2017/10 英語 研究論文(学術雑誌) 公開
Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai, Young Hak Kim Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai, Young Hak Kim Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai, Young Hak Kim Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Oncotarget, 8, 42, 71805-71816 Oncotarget, 8, 42, 71805-71816 Oncotarget, 8, 42, 71805-71816 2017/09/22 英語 研究論文(学術雑誌) 公開
Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report. Molecular and clinical oncology, 7, 2, 295-297 Molecular and clinical oncology, 7, 2, 295-297 Molecular and clinical oncology, 7, 2, 295-297 2017/08 英語 研究論文(学術雑誌) 公開
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takahiro Tsuji, Takashi Nomizo, Tomoko Funazo, Yuto Yasuda, Toyohiro Hirai Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takahiro Tsuji, Takashi Nomizo, Tomoko Funazo, Yuto Yasuda, Toyohiro Hirai Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takahiro Tsuji, Takashi Nomizo, Tomoko Funazo, Yuto Yasuda, Toyohiro Hirai EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. Anticancer research, 37, 5, 2721-2725 Anticancer research, 37, 5, 2721-2725 Anticancer research, 37, 5, 2721-2725 2017/05 英語 研究論文(学術雑誌) 公開
Hironori Yoshida, Young Hak Kim Hironori Yoshida, Young Hak Kim Hironori Yoshida, Young Hak Kim Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12, 5, e61-e63 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12, 5, e61-e63 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12, 5, e61-e63 2017/05 英語 研究論文(学術雑誌) 公開
Hironori Yoshida, Young Hak Kim Hironori Yoshida, Young Hak Kim Hironori Yoshida, Young Hak Kim Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer. Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer. Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer. Annals of translational medicine, 5, 7, 165-165 Annals of translational medicine, 5, 7, 165-165 Annals of translational medicine, 5, 7, 165-165 2017/04 英語 公開
Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Scientific reports, 7, 45124-45124 Scientific reports, 7, 45124-45124 Scientific reports, 7, 45124-45124 2017/03/23 英語 研究論文(学術雑誌) 公開
Keitaro Yamane, Hisamichi Naito, Taku Wakabayashi, Hironori Yoshida, Fumitaka Muramatsu, Tomohiro Iba, Hiroyasu Kidoya, Nobuyuki Takakura Keitaro Yamane, Hisamichi Naito, Taku Wakabayashi, Hironori Yoshida, Fumitaka Muramatsu, Tomohiro Iba, Hiroyasu Kidoya, Nobuyuki Takakura Keitaro Yamane, Hisamichi Naito, Taku Wakabayashi, Hironori Yoshida, Fumitaka Muramatsu, Tomohiro Iba, Hiroyasu Kidoya, Nobuyuki Takakura Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells. Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells. Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells. Scientific reports, 6, 30941-30941 Scientific reports, 6, 30941-30941 Scientific reports, 6, 30941-30941 2016/08/08 英語 研究論文(学術雑誌) 公開
Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takashi Nakaoku, Yoshitaka Yagi, Takahiro Tsuji, Takashi Nomizo, Michiaki Mishima Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takashi Nakaoku, Yoshitaka Yagi, Takahiro Tsuji, Takashi Nomizo, Michiaki Mishima Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takashi Nakaoku, Yoshitaka Yagi, Takahiro Tsuji, Takashi Nomizo, Michiaki Mishima Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Molecular and clinical oncology, 5, 1, 213-215 Molecular and clinical oncology, 5, 1, 213-215 Molecular and clinical oncology, 5, 1, 213-215 2016/07 英語 研究論文(学術雑誌) 公開
Yuichi Sakamori, Young Hak Kim, Hironori Yoshida, Takashi Nakaoku, Hiroki Nagai, Yoshitaka Yagi, Hiroaki Ozasa, Michiaki Mishima Yuichi Sakamori, Young Hak Kim, Hironori Yoshida, Takashi Nakaoku, Hiroki Nagai, Yoshitaka Yagi, Hiroaki Ozasa, Michiaki Mishima Yuichi Sakamori, Young Hak Kim, Hironori Yoshida, Takashi Nakaoku, Hiroki Nagai, Yoshitaka Yagi, Hiroaki Ozasa, Michiaki Mishima Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Molecular and clinical oncology, 3, 2, 334-340 Molecular and clinical oncology, 3, 2, 334-340 Molecular and clinical oncology, 3, 2, 334-340 2015/03 英語 研究論文(学術雑誌) 公開
Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, Yoshitaka Yagi, Takashi Nakaoku, Michiaki Mishima Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, Yoshitaka Yagi, Takashi Nakaoku, Michiaki Mishima Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, Yoshitaka Yagi, Takashi Nakaoku, Michiaki Mishima High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8, 9, e85-6 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8, 9, e85-6 Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8, 9, e85-6 2013/09 英語 研究論文(学術雑誌) 公開
Azuma, M., Haruna, A., Yoshida, H., Ichikawa, Y., Santo, M., Nishimura, T. Azuma, M., Haruna, A., Yoshida, H., Ichikawa, Y., Santo, M., Nishimura, T. Azuma, M., Haruna, A., Yoshida, H., Ichikawa, Y., Santo, M., Nishimura, T. Severe pneumococcal pneumonia successfully treated with direct hemoperfusion using a polymyxin B immobilized column: Two case reports Severe pneumococcal pneumonia successfully treated with direct hemoperfusion using a polymyxin B immobilized column: Two case reports Severe pneumococcal pneumonia successfully treated with direct hemoperfusion using a polymyxin B immobilized column: Two case reports Respiration and Circulation, 60, 11 Respiration and Circulation, 60, 11 Respiration and Circulation, 60, 11 2012 研究論文(学術雑誌) 公開

  • <<
  • >>
  • 表示
タイトル言語:
講演・口頭発表等
タイトル タイトル(日本語) タイトル(英語) 会議名 会議名(日本語) 会議名(英語) 主催者 主催者(日本語) 主催者(英語) 開催年月日 記述言語 会議種別 公開
非小細胞肺癌初回治療における化学療法+免疫チェックポイント阻害剤併用療法の多施設共同後ろ向き観察研究 非小細胞肺癌初回治療における化学療法+免疫チェックポイント阻害剤併用療法の多施設共同後ろ向き観察研究 第60回日本肺癌学会学術集会 第60回日本肺癌学会学術集会 2019/12 公開
Prospective study for usefulness of plasma DNA on prediction of third generation EGFR tyrosine kinase inhibitors (S-PLAT STUDY). Prospective study for usefulness of plasma DNA on prediction of third generation EGFR tyrosine kinase inhibitors (S-PLAT STUDY). Prospective study for usefulness of plasma DNA on prediction of third generation EGFR tyrosine kinase inhibitors (S-PLAT STUDY). IASLC world conference on lung cancer, Barcelona, Spain IASLC world conference on lung cancer, Barcelona, Spain IASLC world conference on lung cancer, Barcelona, Spain 2019/09 公開
Phase II study of consolidation amrubicin after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer. Phase II study of consolidation amrubicin after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer. Phase II study of consolidation amrubicin after concurrent chemoradiotherapy for patients with limited-stage small cell lung cancer. ASCO annual meeting, Chicago, USA ASCO annual meeting, Chicago, USA ASCO annual meeting, Chicago, USA 2019/06 公開
Nivolumabに耐性を来たした非小細胞肺癌の臨床的特徴の検討. Nivolumabに耐性を来たした非小細胞肺癌の臨床的特徴の検討. 第59回日本肺癌学会学術集会. 第59回日本肺癌学会学術集会. 2018/11 公開
肺がん薬物療法とがん免疫療法の実際. 肺がん薬物療法とがん免疫療法の実際. 左京薬剤師会学術講演会. 左京薬剤師会学術講演会. 2018/04 公開講演、セミナー、チュートリアル、講習、講義 公開
Nivolumab for patients with EGFR mutation-positive non-small cell lung cancer. Nivolumab for patients with EGFR mutation-positive non-small cell lung cancer. Nivolumab for patients with EGFR mutation-positive non-small cell lung cancer. IASLC 18th World Conference on Lung Cancer 2017 IASLC 18th World Conference on Lung Cancer 2017 2017/10/17 公開
EGFR遺伝子変異陽性肺癌への免疫チェックポイント阻害薬の検討. EGFR遺伝子変異陽性肺癌への免疫チェックポイント阻害薬の検討. 第9回 胸部腫瘍セミナー 第9回 胸部腫瘍セミナー 2017/10 公開講演、セミナー、チュートリアル、講習、講義 公開
がん免疫療法の課題. がん免疫療法の課題. 第18 回KTORG講演会. 第18 回KTORG講演会. 2017/07 公開講演、セミナー、チュートリアル、講習、講義 公開
アファチニブの高度暴露可能性が高い患者群(Special Population)の探索. アファチニブの高度暴露可能性が高い患者群(Special Population)の探索. 第15回日本臨床腫瘍学会学術集会 第15回日本臨床腫瘍学会学術集会 2017/07 口頭発表(一般) 公開
EGFR-TKI耐性例における血漿中cfDNAを用いたT790M変異解析の検討. EGFR-TKI耐性例における血漿中cfDNAを用いたT790M変異解析の検討. 第57回日本呼吸器学会学術講演会 第57回日本呼吸器学会学術講演会 2017/04 口頭発表(一般) 公開
タイトル言語:
書籍等出版物
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 出版社 出版社(日本語) 出版社(英語) 出版年月 記述言語 担当区分 公開
吉田博徳, 金永学 吉田博徳, 金永学 最新呼吸器内科・外科学 最新呼吸器内科・外科学 メディカルレビュー社 メディカルレビュー社 2019/10 日本語 分担執筆 公開
吉田博徳 吉田博徳 肺がん化学療法副作用マネジメント 肺がん化学療法副作用マネジメント メジカルビュー社 メジカルビュー社 2019/07 日本語 分担執筆 公開
タイトル言語:
外部資金:競争的資金 (科学研究費補助金)
種別 代表/分担 テーマ(日本語) テーマ(英語) 期間
基盤研究(C) 分担 ドライバー遺伝子陽性肺癌における新規治療戦略の開発 2019/04/01〜2022/03/31